Search

Search Results

• CO-19 | A CASE OF LOSS OF EFFICACY OF EMICIZUMAB AFTER 6 YEARS OF REGULAR USE M.R. Fasulo¹, I. Quaglia¹, A. Colombo¹, C. Lodigiani¹, M.E. Mancuso^1|2 | ¹Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; ²Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy

  Maria Rosaria Fasulo

  14-10-2026

  https://doi.org/10.4081/btvb.2026.629

  0

  PDF: 0

• BEST-05 | LONG-TERM EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A: REAL-WORLD EXPERIENCE ACROSS ALL AGES A. Colombo¹, I. Quaglia¹, M.R. Fasulo¹, C. Lodigiani¹, M.E. Mancuso^1|2 | ¹Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; ²Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy

  Arianna Colombo

  14-10-2026

  https://doi.org/10.4081/btvb.2026.605

  0

  PDF: 0

• CO-68 | ACQUIRED FACTOR XIII DEFICIENCY ASSOCIATED WITH CROHN’S DISEASE: A CHALLENGING DIAGNOSTIC AND THERAPEUTIC CASE A. Colombo¹, A. Dal Buono^2|3, I. Quaglia¹, C. Novembrino⁴, M.R. Fasulo¹, C. Lodigiani¹, M.E. Mancuso^1|2 | ¹Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; ²Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy; ³IBD Center, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; ⁴Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Angelo Bianchi Bonomi, Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milano, Italy

  Arianna Colombo

  14-10-2026

  https://doi.org/10.4081/btvb.2026.678

  1

  PDF: 0

• CO-37 | STEW-EFA STUDY: MULTICENTER EVALUATION OF ONE-STAGE AND CHROMOGENIC ASSAYS FOR EFANESOCTOCOG ALFA MEASUREMENT ON STAGO AND WERFEN PLATFORMS A.C. Molinari¹, M. Marchetti², A. Catalano³, L. Contino⁴, R. De Cristofaro⁵, A.B. Federici⁶, T. Martini⁷, I. Quaglia⁸, R. Rossi⁹, R. Santoro¹⁰, A. Tripodi¹¹, A. Valpreda¹² | ¹Regional Reference Centre for Hemorrhagic Diseases, Department of Hemato-Oncology, IRCCS Istituto Giannina Gaslini, Genova, Italy; ²Department of Immunohematology and Transfusion Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy; ³Società per la Promozione dell'educazione Medica (S.P.E.Me), Italy; ⁴Hemostasis and Thrombosis Unit, AOU SS Antonio e Biagio e C Arrigo, Alessandria, Italy; ⁵Dipartimento di Medicina e Chirurgia Traslazionale, Facoltà di Medicina e Chirurgia "Agostino Gemelli," Università Cattolica S. Cuore, Roma, Italy - Servizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario "A. Gemelli" Istituto di Ricerca e Cura a Carattere Scientifico, Roma, Italy; ⁶School of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy; ⁷Hemophilia Centre, Immune-Hematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza", Torino, Italy; ⁸Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy; ⁹Laboratory of Clinical Chemistry and Hematology, University Hospital of Parma, Italy; ¹⁰Hemophilia, Hemostasis, and Thrombosis Unit, Azienda Ospedaliero Universitaria Dulbecco, Catanzaro, Italy; ¹¹IRCCS Ca' Granda Maggiore Hospital Foundation and Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy; ¹²Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, Turin, Italy, reference laboratory of the Regional Center for Hemostasis and Thrombosis.

  Angelo Claudio Molinari

  14-10-2026

  https://doi.org/10.4081/btvb.2026.647

  0

  PDF: 0